HTN Meds Tied to Lower Mortality After Pancreatic Cancer Diagnosis
The mortality risk was lower for patients exposed to ACE inhibitors in first 3 years after pancreatic cancer diagnosis.
Pancreatic Cancer
Sotorasib May Fulfill Unmet Need in Advanced Pancreatic Cancer
Sotorasib exhibited antitumor activity in a phase 1/2 trial of pretreated patients with KRAS G12C-mutated, advanced pancreatic cancer.
Model Using Routine Clinical Data May Predict Pancreatic Cancer Risk
A model using routine clinical information can predict pancreatic ductal adenocarcinoma after diagnosis of impaired fasting glucose.
Neoadjuvant Chemoradiotherapy Improves Long-Term OS in Pancreatic Cancer
In addition to improved overall survival, patients in the neoadjuvant arm had longer disease-free survival and locoregional failure-free intervals.
Adagrasib Shows Promising Activity in Gastrointestinal Cancers
In the KRYSTAL-1 trial, adagrasib produced a 100% disease control rate in patients with gastrointestinal cancers.
Opioid Use Linked to Survival in Older Patients With Advanced Pancreatic Cancer
The median survival was significantly longer in patients who received opioid prescriptions than in those who did not.
Eryaspase Does Not Improve PFS or OS in Advanced Pancreatic Cancer
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
COVID-19 Pandemic Did Not Affect Care of Pancreatic Cancer Patients
Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.
Sintilimab Improves Response to Chemotherapy in Advanced Pancreatic Cancer
The improvement in response did not translate to a survival benefit.
New Symptoms ID’d That May Indicate Pancreatic Cancer
Researchers identified 23 symptoms associated with pancreatic ductal adenocarcinoma.
- Loading...
Loading...
Next post in Pancreatic Cancer
Loading... 
Loading...